匹立昔尔
| 中文名称 | 匹立昔尔 |
|---|---|
| 中文同义词 | 匹立昔尔;化合物 T13821 |
| 英文名称 | Pirinixil |
| 英文同义词 | 2-[[4-Chloro-6-(2,3-dimethylphenylamino)-2-pyrimidinyl]thio]-N-(2-hydroxyethyl)acetamide;2-[[4-Chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]thio]-N-(2-hydroxyethyl)acetamide;Pirinixil;Acetamide, 2-[[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]-N-(2-hydroxyethyl)- |
| CAS号 | 65089-17-0 |
| 分子式 | C16H18ClN3OS |
| 分子量 | 366.87 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 65089-17-0.mol |
| 结构式 |  |
匹立昔尔 性质
| 熔点 | 145°C |
|---|---|
| 沸点 | 609.6±55.0 °C(Predicted) |
| 密度 | 1.2894 (rough estimate) |
| 折射率 | 1.6100 (estimate) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 13.27±0.46(Predicted) |
Pirinixil 是一种低毒性降血脂药。
Pirinixil is a hypolipidemic agent of low toxicity. Total cholesterol is reduced by Pirinixi in the spleen, kidney and heart of rats. Pirinixil decreases the estimated total body cholesterol approximately 40%. Pirinixil increases plasma cholesterol levels significantly without affecting plasma triglycerides. Liver cholesterol and triglycerides are markedly reduced by Pirinixil, while combined plasma and liver lipid levels decrease approximately 20%. Liver HMG-CoA reductase activity is not affected, but cholesterol 7α-hydroxylase is significantly reduced by Pirinixil.